Miguel
Alcoceba Sánchez
Publicaciones en las que colabora con Miguel Alcoceba Sánchez (26)
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
2018
-
Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73
2017
-
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106
-
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array
Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751
2015
2014
-
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Leukemia, Vol. 28, Núm. 2, pp. 391-397
-
Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction
Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234
-
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma
Blood, Vol. 122, Núm. 8, pp. 1448-1454
-
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia
Leukemia, Vol. 27, Núm. 8, pp. 1722-1728
-
The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma
Annals of Hematology, Vol. 92, Núm. 1, pp. 97-100
2012
-
Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma
European Journal of Haematology, Vol. 89, Núm. 4, pp. 328-335
-
Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: Antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype
American Journal of Pathology, Vol. 181, Núm. 5, pp. 1879-1888
2011
-
Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain)
Tissue Antigens, Vol. 78, Núm. 4, pp. 249-255
-
Upregulation of dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients
Haematologica, Vol. 96, Núm. 3, pp. 468-471
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
-
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
Blood, Vol. 114, Núm. 1, pp. 148-152
2008
-
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytoehrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis
Blood, Vol. 112, Núm. 7, pp. 2709-2712
-
Clinical and prognostic value of discrepancies in microsatellite dna regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting
Transplantation, Vol. 86, Núm. 7, pp. 983-990